Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

55P - Engineering of chimeric cytokine receptors (CCR) to induce IL-7 signaling to CAR-T cells for solid tumor treatment

Date

12 Dec 2024

Session

Poster Display session

Presenters

Marta Soria Castellano

Citation

Annals of Oncology (2024) 24 (suppl_1): 1-6. 10.1016/iotech/iotech100743

Authors

M. Soria Castellano1, S. Colell2, T. Lobo-Jarne2, C.A. Di Trani2, M. Giménez-Alejandre2, P. Barbao2, I. Andreu-Saumell2, H. Calderon2, J. Castellsagué2, A. Rodriguez Garcia3, S. Guedan2

Author affiliations

  • 1 Universitat de Barcelona - Facultat de Medicina, Barcelona/ES
  • 2 IDIBAPS - Fundació de Recerca Clinic Barcelona - Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona/ES
  • 3 IDIBAPS - Fundació de Recerca Clinic Barcelona, Barcelona/ES

Resources

This content is available to ESMO members and event participants.

Abstract 55P

Background

Clinical efficacy of CAR-T cells in solid tumors has been limited due to poor expansion and survival. Most CAR constructs provide signal 1 and 2. Current strategies for providing signal 3 mainly rely on constitutive interleukin signaling, while achieving inducible signaling remains a challenging and highly pursued goal in the field. We hypothesized that adding the intracellular domain of the IL-7 cytokine receptor or its activation motifs to induce signal 3 upon antigen recognition would enhance CAR-T cell activation/persistence.

Methods

CCRs were designed by fusing a scFv to the IL-7Rα intracellular domain with the IL-7Rα or CD8 transmembrane domain. We also created second-generation ICOS or CD28-based CARs incorporating IL-7Rα motifs in different conformations. Construct expression and functionality were assessed in vitro and in vivo.

Results

CCRs were efficiently expressed on the T-cell membrane. In single transduction, CCRs failed to induce STAT5 signaling upon antigen recognition unlike a previously described constitutively active IL-7R (C7R). When the extracellular domain of the C7R was replaced by a scFv, STAT5 activation was not complete, suggesting either some steric concerns or that optimization of the CCR extracellular domain may be needed for correct homodimerization. In co-transduction with a CAR, CCRs did not provide a cytotoxic nor a proliferative advantage. Next, we explored the addition of IL-7Rα signaling motifs within a CAR construct. In vitro, we observed differences in terms of expression and cytotoxicity among the different constructs. Using a model of continuous antigen exposure, some IL7R-based constructs revealed enhanced cytotoxicity compared to the control. In vivo, IL7-based CARs behaved similarly to the control CAR, showing no clear advantage in terms of antitumor activity.

Conclusions

By generating and testing several conformations of IL-7R-based CARs and CCRs, we demonstrate that when IL-7Rα signaling domains are included in these receptors they lack signaling upon antigen recognition. Further analysis of CCR homo/heterodimerization with the IL-2Rɣ will be presented. We believe that these findings may shed light on dynamics of cytokine signaling and allow the design of an inducible CCR.

Legal entity responsible for the study

The authors.

Funding

Asociación Española Contra el Cáncer.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.